

PRESS RELEASE

Gradientech Reports Promising Interim Performance Data Including Cefiderocol for Expanded QuickMIC® Gram-Negative Panel

Uppsala, Sweden, April 15, 2026. Gradientech today announces encouraging preliminary results from its ongoing performance study evaluating a second gram-negative panel for its rapid antimicrobial susceptibility testing (AST) system, QuickMIC®, testing directly from positive blood cultures. The performance study includes reserve antimicrobials, including cefiderocol, targeting multidrug-resistant bacteria in the management of sepsis.

The study, almost halfway completed, includes patient samples from three hospitals and covers six additional antibiotics, including cefiderocol, meropenem-vaborbactam, aztreonam-avibactam, and ceftolozane-tazobactam—key reserve antibiotic treatments for severe infections.

Intermediate results indicate performance exceeding regulatory requirements across all tested antibiotics. Successful validation of cefiderocol would position QuickMIC® as the only automated AST system capable of testing this antibiotic, which is currently limited in clinical use due to complex and non-standardised AST testing methods.

“We are encouraged by the strong interim results, particularly for cefiderocol, and the potential to expand access to testing of critical last-resort antibiotics with QuickMIC®,” says Sara Thorslund, CEO and co-founder of Gradientech.

QuickMIC® is the fastest IVDR approved solution for phenotypic AST directly from positive blood cultures, delivering results in an average of 2–4 hours and enabling early treatment decisions in the critical management of sepsis patients. The evaluation of cefiderocol is conducted in collaboration with Shionogi. Final clinical study results are expected in Q2 2026.

QuickMIC® and its Gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO

Tel: +46 736 29 35 80

sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit [gradientech.se](https://www.gradientech.se) for more information.